摘要
对20种挥发油类化合物中的对羟基苯甲酸丁酯(butyl-p-hydroxybenzoate,Bpb)的CFTR氯离子通道激活作用进行系统的分子药理学研究。利用稳定共表达人CFTR和对卤族元素碘离子高度敏感的荧光绿蛋白突变体(EYFP)的Fischer大鼠甲状腺(FRT)上皮细胞为筛选模型,测定Bpb对CFTR介导的I-内流速度的影响。发现了Bpb对野生型CFTR的Cl-通道具有显著的激活作用;Bpb不能纠正△F508-CFTR蛋白胞内转运的障碍,但却具有纠正其通道开放障碍的功能;Bpb对G551D突变型CFTRCl-通道无激活作用。激活作用具有可逆和剂量依赖的特点,初步机制分析结果表明,它可能是通过与CFTR直接结合而发挥作用的。首次发现了Bpb对CFTRCl-通道有激活作用,为深入研究Bpb的药理学作用提供了新方向,使其有可能成为治疗CFTR有关疾病的先导药物。
This study is to investigate the activation effect of butyl-p-hydroxybenzoate (Bpb) on cAMP-dependent cystic fibrosis transmembrane conductance regulator (CFTR) chloride chainnel gating. A stably transfected Fischer rat thyroid (FRT) epithelial cell lines co-expressing human CPTR and a green fluorescent protein mutant with ultra-high halide sensitivity (EYFP) were used to measure CFTR-mediated iodide influx rates. Bpb was identified as an effective activator of wild-type CFTR chloride channel, it can correct △F508-CPTR gating defects but not processing defect. Bpb can't potentiate G551D-CFTR channel gating. The activity was reversible and dose-dependent. The study also provided clues that Bpb activates CFTR chloride channel through a direct binding mechanism. Our study identified Bpb as a novel structure CFTR activator. Bpb may be useful for probing CFTR channel gating mechanisms and as a lead compound to develop pharmacological therapy for CFTR-related disease.
出处
《药学学报》
CAS
CSCD
北大核心
2009年第1期32-37,共6页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(30570864)
教育部"新世纪优秀人才支持计划"项目(NCET-07-0406)
辽宁省"高等学校优秀人才支持计划"项目(2006R33)